NASDAQ OMX

Point Blank Enterprises Acquires United Shield International Limited

Dela

Expands global capabilities to offer complete systems for protective solutions including, body armor, hard armor plates, shields, helmets, and bomb suits worldwide

POMPANO BEACH, Fla., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Point Blank Enterprises ("Point Blank" or "PBE"), the worldwide leader in the production of soft body armor and related protective solutions, announced today that it has successfully completed its acquisition of United Shield International Limited (USIL), a ballistic armor manufacturer located in Andover, Hampshire, United Kingdom.

Commenting on the USIL acquisition, Daniel Gaston, Chief Executive Officer of Point Blank Enterprises, Inc., stated, "The acquisition of USIL further strengthens our product and technology portfolio in personal body armor protection, while adding new capabilities in the areas of manufacturing hard armor products, helmets, plates, shields, and EOD suits.  Our businesses have complementary assets and will offer advanced products to the military and law enforcement agencies of countries around the world which support global security.  We are delighted to bring United Shield International Limited into our organization and look forward to working with its team to leverage our joint portfolios and skillsets, while providing protection to those men and women protecting our streets and in combat around the world."

Founded in 2005 United Shield International Limited is one of the leading manufacturers in the world of personal ballistic and fragmentation protection and fragmentation equipment, with design and manufacturing operations in Andover, Hampshire, in the United Kingdom. United Shield's management team and staff have more than eighty years collective specialist experience and expertise of designing and manufacturing ballistic helmets, body armor, ballistic shields, hard armor plates, EOD/IED protection equipment, mine clearance and demining equipment and a variety of other ballistic and fragmentation protection products.

The Company operates from a modern 12,000 ft2 facility in Andover, Hampshire, close to London, where it maintains the highest quality control standards, using state of the art machinery and manufacturing techniques. USIL supplies ballistic and fragmentation protection equipment to many Military units, as well as the Police, Emergency Services, Prison and Security services, and export to more than eighty countries around the world. United Shield International is an ISO 9001:2008 and ISO 14001:2004 certified company. USIL ensures that all customers receive a high level of service, and the finest products offering the highest levels of protection, and top quality workmanship.

Michael Foreman, Executive Vice President of International Business Develop for PBE, added, "We are very excited about this strategic acquisition of USIL and look forward to the growth it will bring for our Company and the added protective solutions and diverse products for our customers.  It is our privilege to serve the military and law enforcement personnel around the world who are dedicated to making the world a safer place, and the advanced capabilities of USIL will enhance our ability to provide our customers with the highest performing products, while expediting development of next generation protective solutions for those around the world."

About Point Blank Enterprises, Inc.

Point Blank Enterprises, Inc. ("PBEI") is a leading provider of high performance protective solutions, including bullet, fragmentation, and stab resistant apparel and related accessories. Through its key brands, Point Blank Body Armor, Protective Apparel Corporation of America (PACA), Protective Products, PARACLETE®, The Protective Group (TPG), Advanced Technology Group (ATG), First Tactical, and Gould & Goodrich (G&G), the Company ranks as the largest global supplier of ballistic armor systems and systems integrator in the world.  The Company's ballistic solutions have been credited with saving countless lives for the most important customers in the world, including the U.S. Armed Forces, Department of Defense, Federal Government and law enforcement, corrections and security personnel, both domestically and abroad.  For more information on our Company, please visit our website at www.pointblankenterprises.com.

PBE Company Contact:

Michael Foreman
Point Blank Enterprises
Tel: 407-448-6139
Email: mforeman@pbearmor.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Point Blank Enterprises via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder20.11.2017 08:00Pressmeddelande

STOCKHOLM - November 20, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a study with the lead compound GR3027 in patients with idiopathic hypersomnia. The objectives of the study (protocol UCAB-CT-03) are to assess the safety and pharmacokinetics, and to evaluate the exploratory efficacy of GR3027 in patients with idiopathic hypersomnia. Idiopathic hypersomnia (IH) is a severe orphan disease characterized by chronic excessive daytime sleepiness (EDS). It is a lifelong debilitating condition with a profound effect on the patient's quality of life. There are no approved treatments for IH but several wake-promoting treatments are used off-label. However, they are inadequate to alleviate symptoms in most patients, and medication-refractory symptoms or medication intolerance prevents control of symptoms in approximately one-quarter of IH patients.

Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder20.11.2017 08:00Pressmeddelande

STOCKHOLM - November 20, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a study with the lead compound GR3027 in patients with idiopathic hypersomnia. The objectives of the study (protocol UCAB-CT-03) are to assess the safety and pharmacokinetics, and to evaluate the exploratory efficacy of GR3027 in patients with idiopathic hypersomnia. Idiopathic hypersomnia (IH) is a severe orphan disease characterized by chronic excessive daytime sleepiness (EDS). It is a lifelong debilitating condition with a profound effect on the patient's quality of life. There are no approved treatments for IH but several wake-promoting treatments are used off-label. However, they are inadequate to alleviate symptoms in most patients, and medication-refractory symptoms or medication intolerance prevents control of symptoms in approximately one-quarter of IH patients.

Integrum uppmärsammas av Frankrikes president Emmanuel Macron och Stefan Löfven17.11.2017 19:02Pressmeddelande

PRESSINFORMATION 17 november 2017                                  Integrum blev vid fredagens EU-toppmöte i Göteborg som ett av få inbjudna att presentera bolagets tankestyrda proteser för Frankrikes president Emmanuel Macron och Stefan Löfven. Detta i samband med det strategiska partnerskap för innovation mellan Frankrike och Sverige som undertecknades vid mötet med mål att presentera konkreta framsteg inom två år. Integrum var utvalt som ett bra exempel på innovativt företag som utvecklar avancerade medicintekniska produkter där samspelet mellan människa och teknik skapar stort värde för användaren. Under mötet med president Emmanuel Macron och Stefan Löfven demonstrerades Integrums världsunika proteser som styrs med hjälp av tankekraft. Tekniken möjliggör att personer kan få en protes direkt kopplat till skelett, nerver och muskler utan att ha elektroder tillfälligt fästa utanpå huden. "Det är självklart mycket hedrande att I

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research17.11.2017 18:07Pressmeddelande

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goa

Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa17.11.2017 17:00Pressmeddelande

CHARLOTTE, N.C., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as Lead Agent on a senior secured credit facility to support Sentinel Capital Partners in its acquisition of Nekoosa ("Nekoosa" or the "Company"). Headquartered in Nekoosa, Wisconsin, the Company is a leading manufacturer of specialty paper and film products used in the graphics and commercial print markets, including application and pressure-sensitive tapes, specialty synthetic papers, sheeted digital and offset grade carbonless paper, and extruded film products. Nekoosa serves a highly diverse base of more than 70,000 commercial print and graphics shops in 65 countries. Barings served as lead senior lender on the transaction, which included a senior term loan and a revolving credit facility. "Sentinel is pleased to have Barings' support on our investment in Nekoosa," said Scott Perry, a partner with Sentinel Capital Partner

At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking16.11.2017 23:29Pressmeddelande

ExaScaler and PEZY Computing Also Take Top Three Green500 Positions DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) -- At SC17, ExaScaler and PEZY Computing unveiled their Gyoukou supercomputer whose Green500 and Top500 rankings attest to a unique combination of high efficiency and computing power. The Gyoukou supercomputer is installed at the Yokohama Research Institute in Japan. (Video: PEZY Liquid immersion cooling) PEZY supercomputers leverage 48V Factorized Power, a high efficiency, high density power distribution architecture. PEZY's CPUs are co-packaged with Vicor's Power-on-Package ("PoP") Modular Current Multipliers ("MCMs"), which enable efficient, direct 48V to sub-1V current multiplication at the XPU. ExaScaler and PEZY Computing also achieved the #1, #2 and #3 positions on the Green500. These supercomputer system installations also utilize 48V Factorized Power. Come see us at SC17 at Booth 633 where ExaScaler / PEZY Computing will be

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum